{"id":"rifabutin-rifampin","safety":{"commonSideEffects":[{"rate":null,"effect":"Discoloration of body fluids (orange-red)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Uveitis (rifabutin)"},{"rate":null,"effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL444633","moleculeType":"Small molecule","molecularWeight":"847.02"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs bind to the bacterial RNA polymerase β-subunit and block RNA synthesis, making them bactericidal against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC). Rifabutin has a slightly different spectrum and is often preferred in patients on certain antiretroviral drugs due to fewer drug interactions, while rifampin is the first-line agent for tuberculosis. They are prodrugs that require activation in some organisms.","oneSentence":"Rifabutin and rifampin are rifamycin antibiotics that inhibit bacterial RNA polymerase, preventing transcription and killing mycobacteria and other bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:01.176Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (rifampin)"},{"name":"Mycobacterium avium complex (MAC) prophylaxis and treatment (rifabutin)"},{"name":"Tuberculosis in HIV-positive patients (rifabutin preferred due to drug interactions)"}]},"trialDetails":[{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05766267","phase":"PHASE2, PHASE3","title":"Short-course Regimens for the Treatment of Pulmonary Tuberculosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2023-11-21","conditions":"Tuberculosis, Pulmonary, Tuberculosis Infection","enrollment":288},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT02256696","phase":"PHASE2","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-04-29","conditions":"Pulmonary Tuberculosis","enrollment":157},{"nctId":"NCT04672525","phase":"PHASE3","title":"Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","status":"RECRUITING","sponsor":"Tourcoing Hospital","startDate":"2021-11-08","conditions":"Prosthetic Infection","enrollment":436},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02024555","phase":"PHASE2","title":"Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-03","conditions":"Sarcoidosis; Antimycobacterial Therapy","enrollment":97},{"nctId":"NCT03478033","phase":"NA","title":"Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Public Health Clinical Center","startDate":"2018-04-15","conditions":"Tuberculosis, Pulmonary, AIDS","enrollment":230},{"nctId":"NCT01601626","phase":"PHASE2","title":"Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV","status":"TERMINATED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-07-13","conditions":"HIV Infection, Tuberculosis","enrollment":71},{"nctId":"NCT01231542","phase":"PHASE1","title":"Phase 1, Open Label, Two Arm, Fixed Sequence Study to Evaluate the Effect of Rifampin and Rifabutin on GSK1349572 Pharmacokinetics in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT00598897","phase":"PHASE4","title":"Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1995-08","conditions":"Mycobacterium Avium Complex Lung Disease","enrollment":89},{"nctId":"NCT03164291","phase":"PHASE3","title":"Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1984-06","conditions":"Nontuberculous Mycobacterial Infections","enrollment":170},{"nctId":"NCT00598962","phase":"PHASE4","title":"Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at Tyler","startDate":"1994-12","conditions":"Mycobacterium Avium Complex","enrollment":58},{"nctId":"NCT01341184","phase":"PHASE1","title":"TMC207 +/- Rifabutin/Rifampin","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-10-21","conditions":"Tuberculosis","enrollment":33},{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864},{"nctId":"NCT00877591","phase":"PHASE1","title":"Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2008-04","conditions":"Opioid Dependency, HIV Infections","enrollment":63},{"nctId":"NCT01169038","phase":"PHASE1","title":"Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-07","conditions":"Pulmonary Sarcoidosis, Lung Function","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":313,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["mycobutin/"],"phase":"marketed","status":"active","brandName":"Rifabutin/rifampin","genericName":"Rifabutin/rifampin","companyName":"The University of Texas Health Science Center at Tyler","companyId":"the-university-of-texas-health-science-center-at-tyler","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifabutin and rifampin are rifamycin antibiotics that inhibit bacterial RNA polymerase, preventing transcription and killing mycobacteria and other bacteria. Used for Tuberculosis (rifampin), Mycobacterium avium complex (MAC) prophylaxis and treatment (rifabutin), Tuberculosis in HIV-positive patients (rifabutin preferred due to drug interactions).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}